PANITUMUMAB相关论文
Risk of fatal adverse events associated with bevacizumab,cetuximab,and panitumumab in 25,000 patient
Objective The present meta-analysis was conducted to evaluate the fatal adverse events(FAEs)of targeted drugs including ......
...
根据2007年12月Scrip的报道,Amgen公司的Vectibix(通用名为Panitumumab,帕尼单抗)已经得到欧洲委员会的批准,可用于标准化疗失效的......
Second-line panitumumab as a triweekly dose for patients with wild-typeKRAS exon 2 metastatic colore
Objective: Panitumumab administered as monotherapy in colorectal cancer (CRC) has shown response and disease stabilizati......
用125Ⅰ和111In标记人源化抗EGFR单克隆抗体Panitumumab,在体外用EGFR阳性细胞UM-SCC-22B测定125Ⅰ-Panitumumab和111In-DOTA-Pani......
结直肠癌是癌相关性死亡的第三大死因,转移性结直肠癌患者生存率明显下降,且不少患者对化疗产生耐药.帕尼单抗是第一个全人源单克......
Colorectal cancer constitutes one of the most common malignancies and the second leading cause of death from cancer in t......
Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease:A pote
Monoclonal antibodies against epidermal growth factor receptor(EGFR) are used in the treatment of advanced colorectal ca......
表皮生长因子受体（EGFR）在多种上皮来源的正常细胞和恶性肿瘤细胞中表达，调节影响细胞增殖、分化和凋亡的信号途径。目前用于抑制EGFR......
During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of me......
Introduction: Panitumumab is an EGFR inhibitor approved for use in metastatic refractory colorectal cancer. It is unclea......
Introduction: Panitumumab is an EGFR inhibitor approved for use in metastatic refractory colorectal cancer. It is unclea......
Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the stan......
Case Report: Long-Term Survival in Patient with Cirrhosis of the Liver and Colon Cancer K-ras Wild-T
K-ras wild-type carcinoma is a tumour that is sensitive to treatment with anti-cancer and anti-EGFR drugs: the combinati......
Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasti
Here we report a case of a 70-year-old man who received adjuvant chemotherapy with fluorouracile,folinic acid and oxalip......
分子靶向治疗药物是近年来肿瘤治疗发展最热点的研究领域，以低毒高效的特点逐步成为临床肿瘤治疗的重要部分，目前大量的临床试验集中......
根据2007年12月Scrip的报道，Amgen公司的Vectibix（通用名为Panitumumab，帕尼单抗）已经得到欧洲委员会的批准，可用于标准化疗失效的、非K......
Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal canc
Human epidermal growth factor receptor 2(HER2)signaling pathway activation has been identified as a contributor to de no......
panitumumab（ABX—EGF）是第一个完全人源性的针对表皮生长因子受体（EGFR）的单克隆抗体，现已进入临床试验用于治疗实体肿瘤。如同cetuxim......
用125I和111In标记人源化抗EGFR单克隆抗体Panitumumab,在体外用EGFR阳性细胞UM-SCC-22B测定125I-Panitumumab和111In-DOTA-Panitu......
表皮生长因子受体(epidermal growth factor receptor,EGFR)突变、失调或过表达于许多上皮恶性肿瘤,在肿瘤的生长和分化过程中起重......
